價(jià)格 | 詢價(jià) | ||
包裝 | 100ug | 500ug | 1000ug |
最小起訂量 | 100ug |
發(fā)貨地 | 北京 |
更新日期 | 2024-12-16 |
中文名稱:BLAME蛋白 | 英文名稱:SLAMF8 |
品牌: 百普賽斯 | 產(chǎn)地: 北京 |
保存條件: -20°C to -70°C | 純度規(guī)格: 99.9% |
產(chǎn)品類別: 重組蛋白 | |
貨號: SLAMF8 | 用途范圍: 藥物開發(fā)等 |
規(guī)格: 100ug | 是否進(jìn)口: 否 |
分子別名(Synonym)
BLAME,SLAMF8,CD353
表達(dá)區(qū)間及表達(dá)系統(tǒng)(Source)
Biotinylated Human BLAME, His,Avitag (BLE-H82E4) is expressed from human 293 cells (HEK293). It contains AA Ala 23 - Asp 233 (Accession # Q9P0V8-1).
蛋白結(jié)構(gòu)(Molecular Characterization)
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag?).
The protein has a calculated MW of 27.1 kDa. The protein migrates as 30-35 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
標(biāo)記(Labeling)
Biotinylation of this product is performed using Avitag? technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
蛋白標(biāo)記度(Protein Ratio)
Passed as determined by the HABA assay / binding ELISA.
內(nèi)毒素(Endotoxin)
Less than 1.0 EU per μg by the LAL method.
純度(Purity)
>85% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in 50 mM Sodium Citrate, 150 mM NaCl, pH5.5 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
BLAME(表達(dá)的B淋巴細(xì)胞活化劑巨噬細(xì)胞)也被稱為SLAM家族成員8(SLAMF8),CD353。BLAME是一種細(xì)胞表面受體,在IFN-γ或細(xì)菌激活巨噬細(xì)胞(MΦs)時(shí)表達(dá),是革蘭氏陽性菌和革蘭氏陰性菌對ROS的負(fù)調(diào)節(jié)因子。可能通過B細(xì)胞受體在B譜系承諾和/或信號調(diào)節(jié)中發(fā)揮作用。SLAMF8是一種共刺激分子,在炎癥和免疫抑制中影響巨噬細(xì)胞的激活,對膠質(zhì)瘤細(xì)胞的炎癥反應(yīng)可能有助于膠質(zhì)瘤的免疫治療。
成立日期 | 2010-07-22 (15年) | 注冊資本 | 8000萬人民幣 |
員工人數(shù) | 500人以上 | 年?duì)I業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 醫(yī)藥中間體,原料藥,激素類,氨基糖苷類,中樞神經(jīng)系統(tǒng)用藥 | 經(jīng)營模式 | 工廠,試劑 |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP3年
|
上海嘉定區(qū)澄瀏公路52號
|
2024-12-25 | |
¥1950 |
VIP3年
|
上海滬震實(shí)業(yè)有限公司
|
2024-12-25 | |
¥2100 |
VIP6年
|
上海澤葉生物科技有限公司
|
2024-12-25 | |
¥1800 |
南京安研生物科技有限公司
|
2024-05-27 |